Table 1 Clinicopathological characteristics of high- and low-Fut2 expression groups
Characteristic | Low expression of Fut2 | High expression of Fut2 | p |
|---|---|---|---|
n | 239 | 239 | |
Age, n (%) | 0.113 | ||
< = 65 | 88 (18.4%) | 106 (22.2%) | |
> 65 | 151 (31.6%) | 133 (27.8%) | |
Gender, n (%) | 1.000 | ||
Female | 113 (23.6%) | 113 (23.6%) | |
Male | 126 (26.4%) | 126 (26.4%) | |
Race, n (%) | 0.026 | ||
Asian | 2 (0.7%) | 9 (2.9%) | |
Black or African American | 39 (12.7%) | 24 (7.8%) | |
White | 124 (40.5%) | 108 (35.3%) | |
T stage, n (%) | 0.426 | ||
T1 | 4 (0.8%) | 7 (1.5%) | |
T2 | 39 (8.2%) | 44 (9.2%) | |
T3 | 161 (33.8%) | 162 (34%) | |
T4 | 35 (7.3%) | 25 (5.2%) | |
N stage, n (%) | 0.168 | ||
N0 | 133 (27.8%) | 151 (31.6%) | |
N1 | 56 (11.7%) | 52 (10.9%) | |
N2 | 50 (10.5%) | 36 (7.5%) | |
M stage, n (%) | 0.021 | ||
M0 | 165 (39.8%) | 184 (44.3%) | |
M1 | 42 (10.1%) | 24 (5.8%) | |
Pathologic stage, n (%) | 0.078 | ||
Stage I | 38 (8.1%) | 43 (9.2%) | |
Stage II | 85 (18.2%) | 102 (21.8%) | |
Stage III | 68 (14.6%) | 65 (13.9%) | |
Stage IV | 42 (9%) | 24 (5.1%) | |
Primary therapy outcome, n (%) | 0.186 | ||
PD | 12 (4.8%) | 13 (5.2%) | |
SD | 2 (0.8%) | 2 (0.8%) | |
PR | 10 (4%) | 3 (1.2%) | |
CR | 96 (38.4%) | 112 (44.8%) | |
Age, median (IQR) | 70 (58, 77) | 68 (59, 78) | 0.696 |